JCAR014 / Fred Hutchinson Cancer Center, BMS  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
JCAR014 / BMS
RG9213011, NCT01865617: Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Checkmark In CLL at ASH 2016
Dec 2016 - Dec 2016: In CLL at ASH 2016
Checkmark Data for CLL, NHL, and ALL at ASCO 2016
Jun 2016 - Jun 2016: Data for CLL, NHL, and ALL at ASCO 2016
Checkmark B-cell malignancies at ASH 2015
More
Completed
1/2
204
US
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
CD19-Positive Neoplastic Cells Present, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
03/21
03/21

Download Options